• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

TENEO excimer laser platform approved by FDA for myopia and myopic astigmatism

Press Release
Article

The TENEO excimer laser platform is intended for use for LASIK vision correction surgery for myopia and myopic astigmatism.

myopic eye treated with newly fda approved teneo excimer laser - Image credit: Adobe Stock / ©ra2 studio

(Image credit: Adobe Stock / ©ra2 studio)

Bausch + Lomb Corporation announced the FDA has approved the TENEO Excimer Laser Platform for LASIK vision correction surgery for myopia and myopic astigmatism.

Luc Bonnefoy, president, Global Surgical, Bausch + Lomb, discussed the impact of the decision in a press release from Bausch +Lomb.

“TENEO has been well received and is widely adopted in more than 50 countries around the world, and now U.S. ophthalmologists will benefit from this versatile laser," said Bonnefoy. “The precise engineering of this platform delivers a fast, small, technologically advanced machine that provides an exceptional experience for both surgeons and patients.”1

According to Bausch +Lomb, the TENEO device offers several unique features not offered by previous excimer laser platforms, including improvements on accuracy, efficiency, and usability.

The TENEO device operates at 1,740Hz, which is more than “three times the speed of the laser’s repetition” which helps to “ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.” Furthermore, the platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter, states the company.1-2

In addition to the laser speed, the TENEO sports a “compact design” making it the smallest excimer laser unit available in the United States.1-2

George Waring IV, MD, ophthalmologist and founder and medical director, Waring Vision Institute, Mt Pleasant, SC, commented on the approval.

“FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said Waring IV. “In addition to the technological advantages TENEO offers, the open air feeling around the laser and quiet performance contribute to a comfortable experience for the patient.”1

Those interested can submit information online to be among the first to adopt TENEO.

References
1. Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery. Press release; January 8, 2024. Accessed January 8, 2024.
https://www.businesswire.com/news/home/20240108249683/en/Bausch-Lomb-Receives-FDA-Approval-for-TENEO%E2%84%A2-Excimer-Laser-Platform-for-Myopia-and-Myopic-Astigmatism-LASIK-Vision-Correction-Surgery
2. TENEO an extension of brilliance. Accessed January 8, 2024. https://www.bauschsurgical.com/refractive/teneo/
Related Videos
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
Jacob R. Lang, OD, FAAO
Brianna Rhue, OD, FAAO, FSLS
Justin Kwan, OD, FAAO
Kevin Chan, OD, MS, FAAO, presents "Top 5 myopia management myths and how to overcome them" at AOA 2023 in Washington DC
© 2024 MJH Life Sciences

All rights reserved.